Navigation Links
Study IDs Gene Variants Tied to Sudden Cardiac Death
Date:3/23/2009

Finding could prevent fatal arrhythmias by limiting meds in those with risk factor

MONDAY, March 23 (HealthDay News) -- Fourteen common genetic variants associated with a risk factor for sudden cardiac death have been identified by researchers who analyzed genetic data from more than 13,000 people.

The gene variants they identified influence the QT interval measured on electrocardiograms (EKGs) routinely used by doctors to assess patients' heart health. The QT interval is the time from the beginning of electrical activation of the heart to the end of electrical relaxation, according to background information in a news release about the study.

The researchers said their findings, published online in Nature Genetics, could help prevent heart arrhythmia and prevent sudden cardiac death by limiting the use of medications that affect QT interval in people with these 14 gene variants, which are located in 10 different gene regions.

"It is well-established that prolongation of the QT interval in the general population is a potent and heritable risk factor for sudden death. In addition, QT prolongation results from medications leading to drug-induced cardiac arrhythmias and sudden death. This is a cardiotoxic side effect of scores of medications in widespread use and has been a major barrier to the development of novel drugs," study author Dr. Christopher Newton-Cheh, of the Massachusetts General Hospital (MGH) Center for Human Genetic Research and Cardiovascular Research Center, said in an MGH news release.

"From studies of families with congenital long-QT syndrome, we know that rare mutations with strong effects on ion channel function lead to QT prolongation and sudden death. But the common genetic basis for QT prolongation has been very difficult to establish," he said.

A companion study in the same issue of Nature Genetics looked at more than 15,000 people and confirmed 12 of the 14 variants identified in the first study. It also identified two additional gene regions.

"We were very reassured to see such strong replication in two independent studies," Newton-Cheh said.

While a combination of risk factors -- such as heart disease, older age, being female and use of other medications -- contributes to drug-induced arrhythmias, "it is certainly possible that common genetic variants will add incrementally to risk prediction, " he said.

But, Newton-Cheh added, it's "premature to advocate screening gene variants for risk assessment, but someday it may be possible to identify individuals who are particularly high risk and should avoid" medications that can cause QT prolongation.

More information

The U.S. National Heart, Lung, and Blood Institute has more about long QT syndrome.



-- Robert Preidt



SOURCE: Massachusetts General Hospital, news release, March 22, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Transition Therapeutics Announces Initiation of a Phase Ib Clinical Study of TT-223 in combination with a GLP-1 analogue in Patients with Type 2 Diabetes
2. New Clinical Study News for Treatment of Sinusitis, Sinus Infection and Allergy Sufferers Now Have a New Effective Form of Relief through Sinus Dynamics
3. Study quantifies racial disparities in cancer mortality rates between blacks and whites
4. Herbalife Protein Shake Proven Effective in Clinical Study
5. New study finds daily drinking is biggest risk factor in serious liver disease
6. Mayo Clinic Study Suggests Those Who Have Chronic Pain May Need to Assess Vitamin D Status
7. Mayo Clinic study suggests those who have chronic pain may need to assess vitamin D status
8. Final Patient Completes Treatment In Boehringer Ingelheims RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date
9. Genetics Should Decide Warfarin Dose, Study Reiterates
10. Cognitive decline begins in late 20s, study suggests
11. Study finds most adolescents sent to group homes still involved with drugs/crime seven years later
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study IDs Gene Variants Tied to Sudden Cardiac Death
(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article ... obtaining plastic surgery, largely influenced by the growing popularity of “pretty boys” in both ... notes that standards of male appearance are changing not only in the Asian nation, ...
(Date:8/17/2017)... ... 2017 , ... Pot Valet is a leading provider of premium medical-grade cannabis ... state, and soon, every state in the country, the company offers patients safe, legal, ... altogether. , According to Pot Valet, all California patients have the legal ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... A recent ... to the biopharmaceutical industry in 2016 cited deficiencies in data integrity. The FDA outlines ... Part 11 ruling. , Presented as part of the Beckman Coulter Life ...
(Date:8/16/2017)... Los Angeles, California (PRWEB) , ... August 16, 2017 , ... An August 3rd ... patients that was the subject of a report in JAMA (the Journal of the American ... (BMIs) above 50 were able to achieve BMIs under 30, when compared to patients with ...
(Date:8/16/2017)... ... August 16, 2017 , ... For the second ... England student to educate the public on the impact of concussions. Brooke Mills, ... first-ever National Concussion Awareness Day. , Brooke is working diligently is to raise ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... quarter ended June 30, 2017, and updated its financial ... For the fiscal third quarter, Hill-Rom reported ... per diluted share in the prior-year period. These results ... per diluted share primarily related to the non-cash write-down ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
(Date:7/26/2017)... July 26, 2017 Sancilio Pharmaceuticals Company, Inc. ... clinical trial evaluating Altemia TM , an oral therapy ... Sickle Cell Disease (SCD). The SCOT Trial, is a ... and safety of Altemia TM in pediatric patients ... US IND 125274. ...
Breaking Medicine Technology: